IFLR1000

Gilead Sciences $567 million acquisition of Cell Design Labs

7/12/2017
Private acquisition
Select tab

$ 567 million

Announced

7/12/2017

Overview:

  • Gilead Sciences has acquired Cell Design Labs for $567 million.
  • The acquisition included previously held shares of Cell Design by Kite.  
  • The target company is a bio-pharmaceutical firm and developer of new therapeutics, while the acquirer aims to develop disruptive cell-based therapies.
  • Citi acted as financial adviser to Cell Design Labs.

Katrin Kostadinova - Data analyst 

Jurisdiction:

United States

Deal type:

Private acquisition

Practice area:

M&A

Governing law:

United States

Industry sector:

Pharmaceuticals and life sciences

Firm:
Cooley

Party: Cell Design Labs (Target)

Lawyers: Ben Beerle, Jamie Leigh

Related deals